Finally, recommendations consider post-treatment assessment, specifically guidance for the patient’s initial restaging after they complete treatment and ongoing surveillance using advanced imaging or other methods.
About the Guideline
“Radiation Therapy for HPV-Positive Oropharyngeal Squamous Cell Carcinoma: An ASTRO Clinical Practice Guideline” was based on a systematic evidence review of articles published between January 2000 and May 2023. The multidisciplinary guideline task force included radiation and medical oncologists, head and neck surgeons, a medical physicist and a patient representative. The guideline was developed in collaboration with the American Society of Clinical Oncology (ASCO) and the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) and is endorsed by the European Society for Radiotherapy and Oncology (ESTRO) and the Royal Australian and New Zealand College of Radiologists (RANZCR).
ASTRO's clinical guidelines are intended as tools to promote appropriately individualized, shared decision-making between physicians and patients. None should be construed as strict or superseding the appropriately informed and considered judgments of individual physicians and patients.
ABOUT ASTRO
The American Society for Radiation Oncology (ASTRO) is the largest radiation oncology society in the world, with more than 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals who specialize in treating patients with radiation therapies. Radiation therapy contributes to 40% of global cancer cures, and more than a million Americans receive radiation treatments for cancer each year. For information on radiation therapy, visit RTAnswers.org. To learn more about ASTRO, visit our website and media center and follow us on social media.
Back to HCB News
